Abstract
Background: Recent evidence suggests the beneficial effects of cell therapies and nebulized anticoagulants for acute respiratory distress syndrome (ARDS).
Aim: Determine the therapeutic benefit of a combined cell therapy (alveolar type II cells (ATII), mesenchymal stem cells (MSC), supernatant (SN) ATII, SN MSC) with antithrombin in vitro in a coculture of ATII and alveolar macrophages injured with lipopolysaccharide (LPS).
Methods: Cocultured ATII and alveolar macrophages isolated from rat lungs were injured with LPS (10 ng/ml). Two hours after the injury a combined cell therapy (ATII, MSC, SN ATII, SN MSC) with antithrombin (0.1 ng/ml) was administered. Proinflammatory mediators and coagulant factors were analyzed via qRT-PCR at 18 h. Data are expressed as mean±SEM. Statistical analysis was performed using One-Way-ANOVA and Bonferroni post-hoc test (statistical significance p≤0.05).
Results: Proinflammatory mediators and coagulant factors were significantly increased after LPS administration. After administering the different treatments compared the expression of IL1β, IL6, TF PAI-1 and Plasminogen was not as high as in the LPS group.
Conclusions: The results indicate that combined cell therapy with antithrombin are able to attenuate inflammation and coagulation in vitro in a coculture of ATII and macrophages. Both treatments together are able to face different processes involved in lung injury.
Footnotes
Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3347.
This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2020
